<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Extraction extraction-result-138 - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Extracted Data Details for extraction-result-138</h1>

        <div class="section">
            <h2>Extracted Data (Header)</h2>
            <div class="info-section">
                <p><strong>Extraction ID:</strong> extraction-result-138</p>
                <p><strong>Extraction Schema Used (ID):</strong> <a href="../schemas/extraction-schema-9.html">extraction-schema-9</a></p>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of combination therapy strategies used to overcome late or acquired immunotherapy resistance in melanoma, including details on therapy types, mechanisms of resistance, rationale for combinations, study design, clinical or preclinical outcomes, biomarkers, adverse events, and any reported limitations or failures.</div>
                <p><strong>Paper ID:</strong> paper-29ba8e1d2eed039a27636f9a572e865c65d134df</p>
                <p><strong>Paper Title:</strong> <a href="https://www.semanticscholar.org/paper/29ba8e1d2eed039a27636f9a572e865c65d134df" target="_blank">Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells</a></p>
                <p><strong>Paper Venue:</strong> Nature</p>
                <p><strong>Paper TL;DR:</strong> It is demonstrated that targeting PI3Kγ with a selective inhibitor can reshape the tumour immune microenvironment and promote cytotoxic-T-cell-mediated tumour regression without targeting cancer cells directly.</p>
                <p><strong>Cost:</strong> 0.014</p>
            </div>
        </div>

        <div class="section">
            <h2>Extracted Data (Details)</h2>
            <div class="extraction-instance-container" id="e138.0">
                <h3 class="extraction-instance">Extracted Data Instance 0 (e138.0)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of combination therapy strategies used to overcome late or acquired immunotherapy resistance in melanoma, including details on therapy types, mechanisms of resistance, rationale for combinations, study design, clinical or preclinical outcomes, biomarkers, adverse events, and any reported limitations or failures.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>IPI-549 + ICB</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Selective PI3K-γ inhibitor (IPI-549) combined with immune checkpoint blockade (anti-PD-1 and/or anti-CTLA-4)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Preclinical combination strategy that pairs a myeloid-targeted selective PI3K-γ small molecule inhibitor (IPI-549) with immune checkpoint inhibitors (anti-PD-1 and/or anti-CTLA-4) to overcome tumor-associated myeloid cell (TAMC)-mediated resistance to checkpoint blockade by reprogramming suppressive myeloid cells and restoring T cell effector function.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>here</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>combination_therapy_name</strong></td>
                            <td>IPI-549 (PI3K-γ inhibitor) combined with anti-PD-1 and/or anti-CTLA-4 checkpoint blockade</td>
                        </tr>
                        <tr>
                            <td><strong>therapy_components</strong></td>
                            <td>IPI-549 (selective PI3K-γ inhibitor, oral, 15 mg/kg/day in mice), anti-PD-1 antibody (clone RMP1-14, 250 μg/mouse, i.p.), anti-CTLA-4 antibody (clone 9H10, 100 μg/mouse, i.p.)</td>
                        </tr>
                        <tr>
                            <td><strong>mechanism_of_resistance_targeted</strong></td>
                            <td>Myeloid-cell (TAMC/MDSC/macrophage) mediated immunosuppression driven by PI3K-γ signaling: suppressive TAMCs reduce CD8+ T cell infiltration and function (high Arg-1, TGF-β, IDO; M2-like phenotype), producing resistance to PD-1/CTLA-4 blockade.</td>
                        </tr>
                        <tr>
                            <td><strong>rationale_for_combination</strong></td>
                            <td>Selective inhibition of PI3K-γ in myeloid cells reprograms TAMCs from an immunosuppressive M2-like state to an inflammatory M1-like state, decreasing suppressive mediators and restoring CD8+ T cell infiltration and function; this upregulates PD-1/CTLA-4 on T cells and thereby creates susceptibility to checkpoint blockade—so combining IPI-549 with anti-PD-1 and/or anti-CTLA-4 should yield synergistic anti-tumor immunity.</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>Preclinical in vivo mouse tumor models (multiple syngeneic models; focused experiments in ICB-resistant models)</td>
                        </tr>
                        <tr>
                            <td><strong>patient_population</strong></td>
                            <td>Mouse syngeneic tumor models including: B16-GM-CSF melanoma (B16-GMCSF) as a melanoma model engineered to recruit suppressive myeloid cells, 4T1 breast carcinoma, CT26 and MC38 colon carcinoma, LLC lung carcinoma; experiments used immunocompetent C57BL/6J and BALB/c mice (10–15 mice per group typically).</td>
                        </tr>
                        <tr>
                            <td><strong>outcomes</strong></td>
                            <td>Key preclinical outcomes: (1) IPI-549 monotherapy produced tumor growth inhibition in TAMC-rich models (e.g., B16-GMCSF 24–56% TGI range; CT26, MC38, 4T1, LLC also inhibited) but no activity in low-TAMC B16-F10; (2) Combining IPI-549 with anti-PD-1 or anti-CTLA-4 significantly delayed tumor growth in ICB-resistant 4T1 and B16-GMCSF models compared with checkpoint blockade alone; (3) Triple therapy (IPI-549 + anti-PD-1 + anti-CTLA-4) produced complete regressions in 30% of 4T1-bearing mice and 80% of B16-GMCSF-bearing mice (reported in-text), and tumor-free survivors were resistant to tumor re-challenge, indicating durable adaptive immunity; (4) Mechanistic readouts improved: increased CD8+ T cell infiltration, higher CD8/Treg ratio, increased granzyme B and Ki67 in CD8+ T cells, shift toward M1 markers (increased IL-12, iNOS) and decreased M2 markers (TGF-β, Arg-1, IDO).</td>
                        </tr>
                        <tr>
                            <td><strong>biomarkers</strong></td>
                            <td>Predictive/PD biomarkers used or identified: high tumor infiltration by suppressive myeloid cells (CD11b+ TAMCs) identifies tumors likely to benefit; myeloid phenotype markers (M1/M2 ratio: MHCII, CD206; gene expression: Arg1, TGF-β, IDO down; IL-12, NOS2/iNOS up); immune biomarkers: CD8/Treg ratio, CD8+ granzyme B, PD-1 and CTLA-4 upregulation on T cells after IPI-549; ex vivo PD assay: pAKT (S473) inhibition in CD14+ monocytes in human whole blood; functional human PBMC MDSC suppression assay showed reversal of suppression with IPI-549.</td>
                        </tr>
                        <tr>
                            <td><strong>adverse_events</strong></td>
                            <td>No preclinical toxicity or adverse-event data are reported in this paper for the combinations; the authors note a Phase 1/1b trial is ongoing (NCT02637531) but do not present clinical safety data here.</td>
                        </tr>
                        <tr>
                            <td><strong>limitations_or_failures</strong></td>
                            <td>Limitations reported in the study: (1) IPI-549 had no anti-tumor activity in tumors with low suppressive TAMCs (e.g., B16-F10), indicating the approach is effective primarily in TAMC-rich tumors; (2) IPI-549 did not delay tumor growth when TAMCs were depleted (anti-CD11b depletion), supporting dependence on myeloid cells; (3) double checkpoint blockade alone failed to produce complete regressions in resistant models (0% in 4T1, 20% in B16-GMCSF), showing baseline resistance; (4) preclinical only — clinical efficacy and safety remain to be established; (5) authors note that non-selective inhibition (e.g., PI3K-δ targeting) may affect T cells/Tregs, complicating interpretation if non-selective inhibitors are used.</td>
                        </tr>
                        <tr>
                            <td><strong>reference</strong></td>
                            <td>De Henau O, Rausch M, Winkler D, Campesato LF, Liu C, Hirschhorn Cymerman D, Budhu S, Ghosh A, Pink M, Tchaicha J, et al. Overcoming Resistance to Checkpoint Blockade Therapy by Targeting PI3K-γ in Myeloid Cells. Nature. 2016 Nov 17;539(7629):443-447. doi:10.1038/nature20554.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells', 'publication_date_yy_mm': '2016-11'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e138.1">
                <h3 class="extraction-instance">Extracted Data Instance 1 (e138.1)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of combination therapy strategies used to overcome late or acquired immunotherapy resistance in melanoma, including details on therapy types, mechanisms of resistance, rationale for combinations, study design, clinical or preclinical outcomes, biomarkers, adverse events, and any reported limitations or failures.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Dual PI3K-γ/δ + anti-PD-1 (Kaneda et al.)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Dual PI3K-γ/δ inhibition combined with anti-PD-1 checkpoint blockade (as reported by Kaneda et al.)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Mentioned comparison: Kaneda et al. combined PD-1 blockade with a dual PI3K γ/δ inhibitor in preclinical studies; this approach similarly aims to reverse myeloid-mediated immune suppression but may have additional effects on T cells due to PI3K-δ inhibition.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>PI3Kγ is a molecular switch that controls immune suppression</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>combination_therapy_name</strong></td>
                            <td>Dual PI3K-γ/δ inhibitor combined with anti-PD-1</td>
                        </tr>
                        <tr>
                            <td><strong>therapy_components</strong></td>
                            <td>Dual PI3K-γ/δ small-molecule inhibitor (not specified in detail in this paper) + anti-PD-1 antibody</td>
                        </tr>
                        <tr>
                            <td><strong>mechanism_of_resistance_targeted</strong></td>
                            <td>Myeloid-cell driven immune suppression via PI3K isoforms, with potential concurrent effects on regulatory T cells and other T cell functions due to PI3K-δ inhibition.</td>
                        </tr>
                        <tr>
                            <td><strong>rationale_for_combination</strong></td>
                            <td>Target myeloid PI3K signaling to relieve immunosuppression and combine with PD-1 blockade to restore/augment T cell-mediated anti-tumor responses; dual γ/δ inhibition may broaden effects on immune populations.</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>Mentioned as preclinical work (Kaneda et al.), not experimentally detailed in this paper.</td>
                        </tr>
                        <tr>
                            <td><strong>patient_population</strong></td>
                            <td>Preclinical mouse models (as referenced), details not provided here.</td>
                        </tr>
                        <tr>
                            <td><strong>outcomes</strong></td>
                            <td>This paper states the results reported by Kaneda et al. were similar in that combining PI3K inhibition with PD-1 blockade improves anti-tumor activity; quantitative outcomes are not provided in this paper.</td>
                        </tr>
                        <tr>
                            <td><strong>biomarkers</strong></td>
                            <td>Not specified in this paper; authors comment that PI3K-δ has known roles in T cell function (especially Tregs) so biomarker interpretation may be confounded.</td>
                        </tr>
                        <tr>
                            <td><strong>adverse_events</strong></td>
                            <td>Not reported here; authors caution that PI3K-δ inhibition can affect T cell function which could alter therapeutic effects and possibly toxicity.</td>
                        </tr>
                        <tr>
                            <td><strong>limitations_or_failures</strong></td>
                            <td>The authors note uncertainty in Kaneda et al.'s results about whether anti-tumor effects are myeloid-dependent or T cell-dependent because PI3K-δ influences T cells and Tregs—this complicates mechanistic attribution.</td>
                        </tr>
                        <tr>
                            <td><strong>reference</strong></td>
                            <td>Kaneda MM, et al. PI3Kγ is a molecular switch that controls immune suppression. Nature. 2016.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells', 'publication_date_yy_mm': '2016-11'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e138.2">
                <h3 class="extraction-instance">Extracted Data Instance 2 (e138.2)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of combination therapy strategies used to overcome late or acquired immunotherapy resistance in melanoma, including details on therapy types, mechanisms of resistance, rationale for combinations, study design, clinical or preclinical outcomes, biomarkers, adverse events, and any reported limitations or failures.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>CSF-1R blockade + ICB (cited)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Colony stimulating factor-1 receptor (CSF-1R) blockade combined with checkpoint immunotherapy</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Mentioned as an example of myeloid-targeting strategies to reverse immune resistance: blocking CSF-1R to target tumor-associated myeloid cells can reverse resistance to immunotherapy in certain tumor contexts.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Targeting myeloid-derived suppressor cells with colony stimulating factor-1 receptor blockade can reverse immune resistance to immunotherapy in indoleamine 2,3-dioxygenase-expressing tumors</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>combination_therapy_name</strong></td>
                            <td>CSF-1R blockade combined with checkpoint blockade (example cited)</td>
                        </tr>
                        <tr>
                            <td><strong>therapy_components</strong></td>
                            <td>CSF-1R inhibitor/antibody (not detailed here) + checkpoint inhibitors (context-dependent)</td>
                        </tr>
                        <tr>
                            <td><strong>mechanism_of_resistance_targeted</strong></td>
                            <td>Elimination or functional modulation of suppressive tumor-associated myeloid cells (MDSCs/TAMs) that limit T cell infiltration and function.</td>
                        </tr>
                        <tr>
                            <td><strong>rationale_for_combination</strong></td>
                            <td>Depleting or reprogramming suppressive myeloid populations reduces immune suppression and can sensitize tumors to checkpoint blockade.</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>Cited preclinical study (Holmgaard et al.); not experimentally performed in this paper.</td>
                        </tr>
                        <tr>
                            <td><strong>patient_population</strong></td>
                            <td>Preclinical models of IDO-expressing tumors (per cited reference); not melanoma-specific in this paper's experiments.</td>
                        </tr>
                        <tr>
                            <td><strong>outcomes</strong></td>
                            <td>Not detailed in this paper; referenced as evidence that myeloid-targeted strategies can reverse immunotherapy resistance.</td>
                        </tr>
                        <tr>
                            <td><strong>biomarkers</strong></td>
                            <td>Not specified here; generally relates to levels of myeloid suppressor cells and IDO expression per the cited work.</td>
                        </tr>
                        <tr>
                            <td><strong>adverse_events</strong></td>
                            <td>Not reported in this paper.</td>
                        </tr>
                        <tr>
                            <td><strong>limitations_or_failures</strong></td>
                            <td>Not detailed here; included as supporting rationale for targeting myeloid compartments.</td>
                        </tr>
                        <tr>
                            <td><strong>reference</strong></td>
                            <td>Holmgaard RB, Zamarin D, Lesokhin A, Merghoub T, Wolchok JD. Targeting myeloid-derived suppressor cells with colony stimulating factor-1 receptor blockade can reverse immune resistance to immunotherapy in indoleamine 2,3-dioxygenase-expressing tumors. EBioMedicine. 2016.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells', 'publication_date_yy_mm': '2016-11'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
        </div>

        <div class="section">
            <h2>Potentially Relevant New Papers (mentioned by this paper)</h2>
            <ol>
                <li>PI3Kγ is a molecular switch that controls immune suppression <em>(Rating: 2)</em></li>
                <li>Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy <em>(Rating: 2)</em></li>
                <li>Targeting myeloid-derived suppressor cells with colony stimulating factor-1 receptor blockade can reverse immune resistance to immunotherapy in indoleamine 2,3-dioxygenase-expressing tumors <em>(Rating: 2)</em></li>
                <li>Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma <em>(Rating: 1)</em></li>
            </ol>
        </div>

        </div>

    </div>
</body>
</html>